Working… Menu

A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04207463
Recruitment Status : Recruiting
First Posted : December 20, 2019
Last Update Posted : June 17, 2020
Information provided by (Responsible Party):
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : May 30, 2021